RESUMEN
Objectives: The cytokine visfatin is increased in obesity and type 2 Diabetes; however, its role in the development of diabetes is still unsettled. The present study aimed to investigate the serum visfatin levels in prediabetic subjects
Methods: Seventeen subjects with Impaired Fasting Glucose [IFG], 44 Impaired Glucose Tolerant [IGT], 16 IFG-IGT and 51 healthy subjects were recruited. Fasting insulin and visfatin were measured using enzyme-linked immunosorbent assay [ELISA] techniques. The Insulin sensitivity Homeostasis Model Assessment [HOMA%S] and B-cell secretory capacity [HOMA%B] were estimated using HOMA-CIGMA software
Results: HOMA%B was significantly lower in IFG [p = 0.0001] and IFG-IGT [p = 0.001] subjects. HOMA%S in IGT [p = 0.0001] and IFG-IGT [p = 0.001] subjects were significantly lower compared to controls. The fasting serum visfatin [ng/ml] level was significantly higher in IFG [5.08 +/- 2.16, p = 0.0001], IGT [4.75 +/- 2.81, p = 0.0001] and IFG-IGT subjects [4.33 +/- 2.68, p = 0.013] compared to controls [2.60 +/- 1.2]. In binary logistic regression analysis, visfatin has found significantly associated with IFG [B = 0.198, p = 0.040], IGT [B = 0.162, p = 0.043] and IFG-IGT [B = 0.188, p = 0.044]. Visfatin was also found significantly correlated with postprandial serum glucose and blood pressure in IGT subjects. Frequency of IFG, IGT and IFG-IGT subjects increased with increasing visfatin concentrations
Conclusions: Serum visfatin appear to be associated with IFG, IGT and IFG-IGT. Postprandial serum glucose and blood pressure are positively associated with visfatin levels in IGT subjects